Using RBN-2397 as a starting point, Zhang et al generated a series of tricyclic derivatives, of which compound 18 exhibited an exceptionally high potency against PARP7 (IC50 = 0.56 nM), a longer half-life, a higher plasma concentration, and a higher tumor growth inhibition in NCI-H1373 tumor-bearing immunodeficient mice than RBN-2397 (Zhang et al, 2023b). Here, TIPARP is linked to neoplasm.